Art

J-GLOBAL ID：201602252555941111   Reference number：16A0864861

Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization

中心窩下2型脈絡膜血管新生に対する硝子体内組織プラスミノーゲン活性化因子およびラニビズマブによる併用療法

Author (9)： Kachi Ikuko (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Yasukawa Tsutomu (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Kato Aki (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Takase Noriaki (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Morita Hiroshi (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Kubota Ayae (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Hirano Yoshio (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Uemura Akiyoshi (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan) ,  Ogura Yuichiro (Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan)
Material： Japanese Journal of Ophthalmology  (Jpn J Ophthalmol)
Volume： 60  Issue： 3  Page： 179-186  Publication year： May. 2016 
JST Material Number： G0421C  ISSN： 0021-5155  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： ranibizumab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A0864861&from=J-GLOBAL&jstjournalNo=G0421C") }}

Author keywords (4)： Age-related macular degeneration ,  Intravitreal ranibizumab ,  Tissue plasminogen activator ,  Type 2 choroidal neovascularization

JST classification (1)： Drug therapy(=pharmacotherapy)for eye diseases  (GP05020E)

Reference (21)：

• Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-72.
• Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology. 2009;116:2135-40.
• Kawasaki R, Wang JJ, Ji GJ, Taylor B, Oizumi T, Daimon M, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology. 2008;115:1376-81.
• Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31.
• Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-4.

Terms in the title (6)： 中心窩 ,  脈絡膜血管新生 ,  硝子体 ,  組織プラスミノーゲン活性化因子 ,  ラニビズマブ ,  併用療法